Multiple Sclerosis | |
|---|---|
| Study Name | Principal Investigator |
| MN43964 – A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab of in Patients with Multiple Sclerosis. Read more. |
Mary Ann Picone, MD |
| GN41791 – A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sclerosis (FENtrepid). Read more. |
Asya Wallach, MD |
| EFC17504 – A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis (FREVIVA). Read more. |
Mary Ann Picone, MD |
| TG1101-RMS406 – Real world experience with BRIUMVI® (ublituximAB-xiiy) treated patients: A longitudinal registry study (ENABLE). Read more. |
Mary Ann Picone, MD |
| CLOU064C12306 – A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib. Read more. |
Mary Ann Picone, MD |
